451 patents
Page 11 of 23
Utility
Lysophosphatidic Acid Receptor 1 (LPAR1) Inhibitor Compounds
8 Sep 22
Tianwei Ma, Liang Wu, Xuejun Zhang
Filed: 18 May 22
Utility
TREM2 Antibodies and Uses Thereof
8 Sep 22
The present invention relates to TREM2 antibodies, and uses thereof, for treating diseases such as neurodegenerative diseases.
Forest Hoyt Andrews, Ross Edward Fellows, Ying Tang, Yaming Wang
Filed: 5 May 22
Utility
Methods and Apparatus for Determining Device Dosage
8 Sep 22
The techniques described herein relate to computerized methods and apparatus for determining a dose injected into a user by one or more medication delivery devices.
Jeffrey Sterling ANDREWS, Xuanyao HE, Jie XUE
Filed: 25 Aug 20
Utility
Relaxin Analogs and Methods of Using the Same
1 Sep 22
Relaxin (RLN) analogs are disclosed including modifications that increase half-life when compared to native, human RLN, that maintain selectivity to the RXFP1 receptor and that provide in vitro and in vivo stability for improved druggability properties and less immunogenicity.
Petra Verdino, Stacey Lynn Lee, Xiaojun Wang
Filed: 31 Jul 20
Utility
Methods and Apparatus for Aspects of a Dose Detection System
1 Sep 22
The techniques described herein relate to computerized methods and apparatus of at least one of for determining whether a dose sensing module is attached to a medication delivery device, such as, for example, with dose detection sensors, for detecting a color of a portion of a medication delivery device to determine a medication contained in the medication delivery device, such as, for example, with a set of LEDs and light sensor for different temperature conditions, and for monitoring a battery life of a battery in the dose sensing module, such as, for example, with current/voltage detection for different temperature conditions.
Marco CORTINOVIS, Bhakti Girish KHANDAGALE, Rossano Claudio MASSARI
Filed: 19 Aug 20
Utility
GIP/GLP1 Agonist Compositions
1 Sep 22
A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.
Vincent John CORVARI, Christopher Sears MINIE, Dinesh Shyamdeo MISHRA, Ken Kangyi QIAN
Filed: 10 May 22
Utility
Systems and Methods for Detecting Cognitive Decline with Mobile Devices
1 Sep 22
Embodiments of the present disclosure relate systems and methods for detecting cognitive decline of a subject using passively obtained data from at least one mobile device.
Richard Jia Chuan CHEN, Luca FOSCHINI, Filip Aleksandar JANKOVIC, Hyun Joon JUNG, Lampros KOURTIS, Vera MALJKOVIC, Nicole Lee MARINSEK, Melissa Anna Maria PUGH, Jie SHEN, Alessio SIGNORINI, Han Hee SONG, Marc Orlando SUNGA, Andrew Daniel TRISTER, Belle TSENG, Roy YAARI
Filed: 9 Jul 20
Utility
Treatment of Genital Psoriasis
1 Sep 22
Methods of treating genital psoriasis, genital pruritus and genital psoriasis sexual activity impairment with anti-IL17A antibodies, including dose regimens and pharmaceutical formulations of anti-IL17A antibodies for use in the treatment of genital psoriasis, genital pruritus and genital psoriasis sexual activity impairment.
Mark Oren Blakely, Alison Jean Potts Bleakman, Chin Hyok Lee, Brian Edward Wagner
Filed: 13 May 22
Utility
PYRIMIDINE-5-CARBOXAMIDE Compound
1 Sep 22
Sra. Gema RUANO PLAZA
Filed: 31 Jul 20
Utility
Dose detection for a medication delivery device
30 Aug 22
The present disclosure relates to a dose detection system in combination with a medication delivery device.
Roy Howard Byerly, Rossano Claudio Massari, Davide Paccioretti, Russell Wayne Perkins
Filed: 12 Aug 21
Utility
Methods of using interleukin-10 for treating diseases and disorders
16 Aug 22
Methods of treating subjects having diseases, disorders, or conditions, including cancer and immune- and inflammatory-related disorders, via the administration of IL-10 in combination with one or more additional agents, and methods and models associated therewith, are provided.
John Brian Mumm, Ivan Ho Chan, Martin Oft
Filed: 7 Nov 14
Utility
(trifluoromethyl)pyrimidine-2-amine compounds
16 Aug 22
Daryl Lynn Smith, Leonard Larry Winneroski, Jr.
Filed: 30 Apr 21
Utility
7,8-DIHYDRO-4H-PYRAZOLO[4,3-c]AZEPINE-6-ONE COMPOUNDS
11 Aug 22
Wenceslao LUMERAS AMADOR, Barbara Jean BRANDHUBER
Filed: 3 Aug 20
Utility
Recombinantly Engineered, Lipase/esterase-deficient Mammalian Cell Lines
11 Aug 22
Mammalian cell lines with reduced expression and/or activity of lipases/esterases, and methods of producing the same are provided.
Christopher Carl FRYE, Troii HALL, Lihua HUANG, Stephanie Lynn SANDEFUR
Filed: 14 Apr 22
Utility
CD200R Agonist Antibodies and Uses Thereof
11 Aug 22
The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.
Stephen J. Demarest, Anja Koester, Scott Charles Potter, Diana Isabel Ruiz, Derrick Ryan Witcher, Xiufeng Wu, Payal Mehta
Filed: 21 Apr 22
Utility
Gitr Antagonists and Methods of Using the Same
11 Aug 22
The present disclosure relates to compounds that bind to human GITR, pharmaceutical compositions comprising such compounds, and methods of using such compounds.
Petra VERDINO, Paul Francis CAIN, Melinda Ann LACERTE, Stacey Lynn LEE, Mark Andrew WORTINGER
Filed: 1 Feb 22
Utility
Processes and Intermediates for the Preparation of 2-(2,6-DICHLOROPHENYL)-1-[(1S,3R)-3-(HYDROXYMETHYL)-5-(3-HYDROXY-3-METHYLBUTYL)-1-METHYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL]ETHENONE
4 Aug 22
Kevin Paul COLE, Neil John KALLMAN, Nicholas Andrew MAGNUS
Filed: 11 Jun 20
Utility
[1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes
2 Aug 22
Michael James Genin, William Glen Holloway, Cynthia Darshini Jesudason, Qing Shi
Filed: 3 Aug 18
Utility
ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
28 Jul 22
The invention is directed to a short term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by deposition of Aβ in the brain, that include Alzheimer's disease (Aβ), Down's syndrome, and cerebral amyloid angiopathy (CAA).
Ronald Bradley Demattos, Michael Carl Irizarry
Filed: 1 Apr 22
Utility
BTLA agonist antibodies and uses thereof
26 Jul 22
Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.
Shane Krummen Atwell, Andrew Charles Vendel, Victor H. Obungu
Filed: 17 Feb 20